XML 46 R32.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Goodwill and Intangible Assets (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract] |
Summary of intangible assets by major asset class | The following sets forth goodwill and intangible assets by major asset class:
|  |  | December 31, 2017 |  | December 31, 2016
| Useful Life (Yrs) | Gross |  | Accumulated Amortization |  | Net Book Value |  | Gross |  | Accumulated Amortization |  | Net Book Value
Indefinite lived: |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill(a) |  |  | $ | 10,513,371 |  |  | $ | — |  |  | $ | 10,513,371 |  |  | $ | 10,513,371 |  |  | $ | — |  |  | $ | 10,513,371 |
Definite lived: |  |  |  |  |  |  |  |  |  |  |  |  |
Patents | 8 – 17 |  | 5,802,528 |  |  | (5,681,673 | ) |  | 120,855 |  |  | 5,802,528 |  |  | (5,618,854 | ) |  | 183,674 |
Licenses | 8 – 17 |  | 1,323,761 |  |  | (1,190,609 | ) |  | 133,152 |  |  | 1,323,761 |  |  | (1,161,861 | ) |  | 161,900 |
CELLECTRA®(b) | 5 – 11 |  | 8,106,270 |  |  | (7,252,108 | ) |  | 854,162 |  |  | 8,106,270 |  |  | (6,825,028 | ) |  | 1,281,242 |
GHRH(b) | 11 |  | 335,314 |  |  | (271,948 | ) |  | 63,366 |  |  | 335,314 |  |  | (240,264 | ) |  | 95,050 |
Bioject (c) | 2 – 15 |  | 5,100,000 |  |  | (1,405,556 | ) |  | 3,694,444 |  |  | 5,100,000 |  |  | (562,222 | ) |  | 4,537,778 |
Other(d) | 18 |  | 4,050,000 |  |  | (2,906,250 | ) |  | 1,143,750 |  |  | 4,050,000 |  |  | (2,681,250 | ) |  | 1,368,750 |
Total intangible assets |  |  | 24,717,873 |  |  | (18,708,144 | ) |  | 6,009,729 |  |  | 24,717,873 |  |  | (17,089,479 | ) |  | 7,628,394 |
Total goodwill and intangible assets |  |  | $ | 35,231,244 |  |  | $ | (18,708,144 | ) |  | $ | 16,523,100 |  |  | $ | 35,231,244 |  |  | $ | (17,089,479 | ) |  | $ | 18,141,765 |
(a) | Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX Pharmaceuticals in June 2009 and the acquisition of Bioject in April 2016 for $3.9 million, $6.2 million and $400,000, respectively.
(b) | CELLECTRA® and GHRH are developed technologies which were recorded from the acquisition of VGX Pharmaceuticals.
(c) | Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the acquisition of Bioject.
(d) | Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.
Schedule of finite-lived intangible assets, future amortization expense | Amortization expense related to intangible assets at December 31, 2017 is expected to be incurred as follows:
Year ending December 31, |
2018 | $ | 1,249,584 |
2019 | 1,066,251 |
2020 | 547,081 |
2021 | 520,414 |
2022 | 492,818 |
Thereafter | 2,133,581 |
| $ | 6,009,729 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 + Details
Name: | us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration